|
1
|
Ehlén A, Brennan DJ, Nodin B, et al:
Expression of the RNA-binding protein RBM3 is associated with a
favourable prognosis and cisplatin sensitivity in epithelial
ovarian cancer. J Transl Med. 8:782010.PubMed/NCBI
|
|
2
|
Weinberg LE, Rodriguez G and Hurteau JA:
The role of neoadjuvant chemotherapy in treating advanced
epithelial ovarian cancer. J Surg Oncol. 101:334–343. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Johnstone RW, Ruefli AA and Lowe SW:
Apoptosis: a link between cancer genetics and chemotherapy. Cell.
108:153–164. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Petrocca F and Lieberman J:
Micromanipulating cancer: microRNA-based therapeutics? RNA Biol.
6:335–340. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Boren T, Xiong Y, Hakam A, et al:
MicroRNAs and their target messenger RNAs associated with ovarian
cancer response to chemotherapy. Gynecol Oncol. 113:249–255. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hebert C, Norris K, Scheper MA, Nikitakis
N and Sauk JJ: High mobility group A2 is a target for miRNA-98 in
head and neck squamous cell carcinoma. Mol Cancer. 6:52007.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Moriyama T, Ohuchida K, Mizumoto K, et al:
MicroRNA-21 modulates biological functions of pancreatic cancer
cells including their proliferation, invasion, and chemoresistance.
Mol Cancer Ther. 8:1067–1074. 2009. View Article : Google Scholar
|
|
8
|
Zhou M, Liu Z, Zhao Y, et al:
MicroRNA-125b confers the resistance of breast cancer cells to
paclitaxel through suppression of pro-apoptotic Bcl-2 antagonist
killer 1 (Bak1) expression. J Biol Chem. 285:21496–21507. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sorrentino A, Liu CG, Addario A, Peschle
C, Scambia G and Ferlini C: Role of microRNAs in drug-resistant
ovarian cancer cells. Gynecol Oncol. 111:478–486. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yang L, Li N, Wang H, Jia X, Wang X and
Luo J: Altered microRNA expression in cisplatin-resistant ovarian
cancer cells and upregulation of miR-130a associated with
MDR1/P-glyco protein-mediated drug resistance. Oncol Rep.
28:592–600. 2012.
|
|
11
|
Fu X, Tian J, Zhang L, Chen Y and Hao Q:
Involvement of microRNA-93, a new regulator of PTEN/Akt signaling
pathway, in regulation of chemotherapeutic drug cisplatin
chemosensitivity in ovarian cancer cells. FEBS Lett. 586:1279–1286.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chen C, Ridzon DA, Broomer AJ, et al:
Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic
Acid Res. 33:e1792005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
|
|
14
|
Li J, Fu H, Xu C, et al: miR-183 inhibits
TGF-beta1-induced apoptosis by downregulation of PDCD4 expression
in human hepatocellular carcinoma cells. BMC Cancer. 10:3542010.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wei ZT, Zhang X, Wang XY, et al: PDCD4
inhibits the malignant phenotype of ovarian cancer cells. Cancer
Sci. 100:1408–1413. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Adams G, Zekri J, Wong H, Walking J and
Green JA: Platinum-based adjuvant chemotherapy for early-stage
epithelial ovarian cancer: single or combination chemotherapy?
BJOG. 117:1459–1467. 2010. View Article : Google Scholar
|
|
17
|
Amaral JD, Xavier JM, Steer CJ and
Rodrigues CM: Targeting the p53 pathway of apoptosis. Curr Pharm
Des. 16:2493–2503. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Dykxhoorn DM: MicroRNAs and metastasis:
little RNAs go a long way. Cancer Res. 70:6401–6406. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Garg M: MicroRNAs, stem cells and cancer
stem cells. World J Stem Cells. 4:62–70. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hummel R, Hussey DJ and Haier J:
MicroRNAs: predictors and modifiers of chemo- and radiotherapy in
different tumour types. Eur J Cancer. 46:298–311. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yu ZW, Zhong LP, Ji T, Zhang P, Chen WT
and Zhang CP: MicroRNAs contribute to the chemoresistance of
cisplatin in tongue squamous cell carcinoma lines. Oral Oncol.
46:317–322. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hummel R, Watson DI, Smith C, et al:
Mir-148a improves response to chemotherapy in sensitive and
resistant oesophageal adenocarcinoma and squamous cell carcinoma
cells. J Gastrointest Surg. 15:429–438. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hamano R, Miyata H, Yamasaki M, et al:
Overexpression of miR-200c induces chemoresistance in esophageal
cancers mediated through activation of the Akt signaling pathway.
Clin Cancer Res. 17:3029–3038. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Jansen AP, Camalier CE, Stark C and
Colburn NH: Characterization of programmed cell death 4 in multiple
human cancers reveals a novel enhancer of drug sensitivity. Mol
Cancer Ther. 3:103–110. 2004.PubMed/NCBI
|
